PMID: 2506594Jan 1, 1989Paper

Clomipramine and mianserin in chronic idiopathic pain syndrome. A placebo controlled study

Psychopharmacology
D LoldrupP Bech

Abstract

The reduction of pain by two antidepressants, clomipramine and mianserin, was, in this study on 253 patients with chronic idiopathic pain syndrome, found to be not better than a placebo when all patients were compared independently of the classification of pain. The improvement rate was around 40% after 6 weeks of treatment when using a 50% or better reduction in pain level. However, in patients who fulfilled a checklist definition of minor to major depression (30% of the total patient material) clomipramine was superior to mianserin and placebo with an improvement rate of 75% after 6 weeks. Using pain curves over time as outcome measure in the various clinical pain categories it was found that both mianserin and clomipramine seemed superior to placebo in patients with tension headache, but in patients with low back pain syndrome placebo was superior to the two antidepressants. No difference among the three treatments was found in patients with burning mouth syndrome or in patients with abdominal pain. These differences underline the importance of studying specific pain syndromes rather than composite groups of patients with idiopathic pain. The clinical significance of these pain curves needs further placebo controlled investi...Continue Reading

References

Mar 1, 1975·Acta Psychiatrica Scandinavica·P BechT G Bolwig
Jul 1, 1975·Journal of Personality and Social Psychology·L Eaves, H Eysenck
Nov 1, 1988·Psychiatry Research·E T MellerupP Plenge
Sep 1, 1986·Acta Psychiatrica Scandinavica·P BechT Vanggaard
Sep 1, 1985·Acta Psychiatrica Scandinavica·W Maier, M Philipp
Aug 1, 1972·Proceedings of the National Academy of Sciences of the United States of America·D BennettE A Boyse
Jan 1, 1983·Clinical Neuropharmacology·T D Walsh
Mar 1, 1984·Archives of General Psychiatry·F M QuitkinP J McGrath
Jul 1, 1983·The British Journal of Psychiatry : the Journal of Mental Science·P BechO J Rafaelsen
Jan 1, 1959·The British Journal of Medical Psychology·M HAMILTON
Jun 1, 1961·Archives of General Psychiatry·A T BECKJ ERBAUGH
Aug 1, 1965·The British Journal of Psychiatry : the Journal of Mental Science·M W CARNEYR F GARSIDE
Dec 1, 1964·International Journal of Neuropharmacology·G STILLE, A SAYERS

❮ Previous
Next ❯

Citations

Dec 3, 2005·Journal of Gastroenterology·Mariko HojoNobuhiro Sato
Jul 27, 2005·Current Gastroenterology Reports·Noel R FajardoNicholas J Talley
Mar 7, 2002·Current Treatment Options in Gastroenterology·Kashyap V. PanganamamulaHenry P. Parkman
Jul 13, 2005·Current Treatment Options in Gastroenterology·Smita L S Halder, Nicholas J Talley
Sep 1, 2007·Current Treatment Options in Gastroenterology·Smita L S Halder, Nicholas J Talley
Nov 4, 2000·The American Journal of Medicine·J L JacksonK Kroenke
Nov 26, 1997·European Journal of Pharmacology·C MestreT Pelissier
Jul 1, 1995·International Journal of Dermatology·D GrinspanF M Stengel
Sep 1, 1993·Acta Psychiatrica Scandinavica·P OnghenaD Verstraeten
Jan 1, 1996·Journal of the American Academy of Nurse Practitioners·J Unger
Oct 22, 2010·BMJ : British Medical Journal·Jeffrey L JacksonPatrick G O'Malley
Jan 13, 2004·Drugs & Aging·Thorsten Nikolaus, Andrej Zeyfang
Dec 20, 2008·Drugs·Bénédicte VerduAlexandre Berney
Dec 31, 2008·World Journal of Gastroenterology : WJG·Shamaila WaseemPeter V Draganov
Jun 24, 2004·Journal of General Internal Medicine·Robert D KeeleyKathryn M Rost
Jun 3, 2014·Expert Opinion on Drug Metabolism & Toxicology·Yan SunRichard W McCallum
Nov 11, 2008·Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics·Yutaka YamazakiYoshimasa Kitagawa
Jun 10, 2005·Alimentary Pharmacology & Therapeutics·M OtakaS Watanabe
Apr 17, 2004·Neurogastroenterology and Motility : the Official Journal of the European Gastrointestinal Motility Society·A N JamesH P Parkman
Aug 25, 2004·Best Practice & Research. Clinical Gastroenterology·Filippo CremoniniNicholas J Talley
Nov 16, 2005·Gastroenterology·Nicholas J TalleyPaul Moayyedi
Mar 15, 2013·Journal of Oral Science·Osamu KomiyamaMisao Kawara
Oct 9, 2012·International Journal of Oral and Maxillofacial Surgery·W J J M MartinT Forouzanfar
Aug 1, 1994·Journal of Pain and Symptom Management·C P Watson
Apr 28, 2004·Pain·Christelle Gremeau-RichardStéphanie Tubert
Nov 8, 2014·The Cochrane Database of Systematic Reviews·Maria KleinstäuberMichael J Lambert
Jul 20, 2007·The Cochrane Database of Systematic Reviews·D Gill, S Hatcher
Feb 7, 2008·The Cochrane Database of Systematic Reviews·D M UrquhartM W van Tulder
Jan 20, 1998·Clinical Pharmacology and Therapeutics·C L DeckersW O Renier
Feb 6, 2008·Alimentary Pharmacology & Therapeutics·A Patrick, O Epstein
Jan 1, 2004·Biological Reviews of the Cambridge Philosophical Society·H P Linder
Nov 18, 2016·The Cochrane Database of Systematic Reviews·Roddy McMillanJoanna M Zakrzewska
Oct 19, 2007·The Cochrane Database of Systematic Reviews·T Saarto, P J Wiffen
Nov 3, 2004·Gastroenterology·Henry P ParkmanUNKNOWN American Gastroenterological Association

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.